Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Infections, Staphylococcal

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Infections, Staphylococcal in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Al-Hassani, M; Billings, SD; Howard, KM; Ishii, S; Mousdicas, N; Perkins, SM; Shimizu, T; Travers, JB; Yi, Q; Zhang, Q1
Connolly, RJ; Dinarello, CA; Dirkes, K; Gelfand, JA; Harris, BH; Schwaitzberg, SD1
DeJoy, SQ; Jeyaseelan, R; Kerwar, SS; Oronsky, AL; Pickett, WC; Torley, LW; Wick, MM; Wissner, A1
Allen, RC; Bessou, G; Descamps-Latscha, B; Halbwachs-Mecarelli, L; Lenoir, G; Sermet-Gaudelus, I; Witko-Sarsat, V1

Other Studies

4 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Infections, Staphylococcal

ArticleYear
Staphylococcal lipoteichoic acid inhibits delayed-type hypersensitivity reactions via the platelet-activating factor receptor.
    The Journal of clinical investigation, 2005, Volume: 115, Issue:10

    Topics: Animals; Calcium; Cell Line; Dermatitis, Atopic; Dinitrofluorobenzene; Drug Hypersensitivity; Drug Synergism; Humans; Hypersensitivity, Delayed; Inflammation; Interleukin-10; Lipopolysaccharides; Mice; Mice, Knockout; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Skin; Staphylococcal Infections; Staphylococcus aureus; Teichoic Acids; Th1 Cells; Th2 Cells

2005
Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia.
    Journal of pediatric surgery, 1994, Volume: 29, Issue:8

    Topics: Animals; Hemodynamics; Leukocyte Count; Organophosphorus Compounds; Platelet Activating Factor; Platelet Count; Rabbits; Sepsis; Staphylococcal Infections; Staphylococcus epidermidis; Thiazoles

1994
Effect of CL 184,005, a platelet-activating factor antagonist in a murine model of Staphylococcus aureus-induced gram-positive sepsis.
    The Journal of infectious diseases, 1994, Volume: 169, Issue:1

    Topics: Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Enterotoxins; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organophosphorus Compounds; Platelet Activating Factor; Staphylococcal Infections; Thiazoles; Time Factors; Tumor Necrosis Factor-alpha

1994
Priming of blood neutrophils in children with cystic fibrosis: correlation between functional and phenotypic expression of opsonin receptors before and after platelet-activating factor priming.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:1

    Topics: Adolescent; Adult; Bronchial Diseases; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Female; Genotype; Humans; In Vitro Techniques; Infant; Inflammation Mediators; Male; Neutrophils; Phenotype; Platelet Activating Factor; Pseudomonas Infections; Receptors, Immunologic; Staphylococcal Infections

1999